AsymBio Kicks Off Construction of Fengxian R&D Building to Establish a Full-Lifecycle, One-Stop Biologics Service Ecosystem

SHANGHAI, July 27, 2026 /PRNewswire/ -- AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), today announced that construction of its new R&D building has officially broken ground at the Shanghai Fengxian site. The project marks a pivotal infrastructure step in strengthening AsymBio's biologics CDMO capabilities and reinforcing the Fengxian site's role as a core development-and-manufacturing hub.

Construction began in May 2026, with full completion and official commissioning slated for the second half of 2027. The eight-story building will occupy approximately 2,500 square meters of land, provide nearly 20,000 square meters of gross floor area, and be constructed in full compliance with green and low-carbon construction standards. The facility will support cell line development, upstream and downstream process development, conjugation process development, drug product development, and comprehensive analytical development services.

Located within AsymBio's Fengxian site, adjacent to the clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs), the building will serve as a dedicated R&D hub. Once operational, it will work in close alignment with the site's production lines to streamline scale-up and commercial manufacturing while shortening overall project timelines.

The Fengxian R&D building will also provide the core physical carrier for the AccPCC (Accelerated PCC platform), an integrated R&D acceleration platform designed to shorten the development timeline from lead to preclinical candidate (PCC) selection. Built around an end-to-end, AI-enabled workflow, AccPCC connects early R&D and CMC with nonclinical evaluation and early clinical translation. The platform delivers full-spectrum technical support spanning lead optimization, developability assessment, and early-stage customized CMC strategy for global biotech partners.

Rui Yang, CEO of AsymBio, commented, "Effective biologics development requires earlier engagement, integrated scientific and CMC decision-making, and manufacturability considerations from the outset. By leveraging cross-site R&D resources across the entire Asymchem Group, AccPCC is designed to improve development efficiency, shorten the path to PCC selection and accelerate science-to-clinic translation. The Fengxian R&D building will be a key enabler of closer integration between early development, scale-up and manufacturing, helping clients reduce handoffs and manage complex programs with greater clarity, continuity and confidence."

About AsymBio

AsymBio, a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), focuses exclusively on biopharmaceutical CDMO services. Backed by Asymchem Group's 30 years of experience and global operations, AsymBio delivers one-stop CDMO services from early-stage and process development to toxicology, clinical, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics, including monoclonal, bispecific, and multispecific antibodies, and protein-based therapeutics, including fusion proteins and recombinant proteins.

For more information, visit www.asymbio.com or follow us on LinkedIn.
Business inquiries: MKT@asymchem.com.cn

Compliance Notes

Forward-Looking Statement Disclaimer: This press release contains forward-looking statements regarding future events and expectations. Actual results may differ materially due to various factors. AsymBio undertakes no obligation to update these statements.

Non-Solicitation Statement: This announcement is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities.

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

AsymBio Kicks Off Construction of Fengxian R&D Building to Establish a Full-Lifecycle, One-Stop Biologics Service Ecosystem

Partners with KACCWA to deploy REALIZER as the Official AI Platform for WABA Korea Expo 2026, helping businesses transform face-to-face meetings into lasting business opportunities.

SEATTLE, July 28, 2026 /PRNewswire/ -- CoBALT, an AI SaaS company specializing in business relationship intelligence, today announced its official expansion into the United States with a strategic partnership with the Korean American Chamber of Commerce of Washington State (KACCWA). Under the agreement signed on July 20, CoBALT's flagship platform, REALIZER, has been selected as the Official AI-powered Business Engagement Platform for WABA Korea Expo 2026.

Scheduled to take place in Seattle from August 14–16, 2026, with a B2B networking program beginning on August 13, WABA Korea Expo serves as a primary gateway connecting Korean and U.S. companies, investors, and industry leaders. Throughout the Expo, REALIZER will be provided to participating exhibitors to digitize, organize, and automate relationship management before, during, and after meetings.

While conventional CRM tools require manual data entry after interactions occur, REALIZER captures the full context of face-to-face meetings from the very first contact. By leveraging AI to automate contact capture, briefing preparation, and personalized follow-ups, REALIZER eliminates traditional follow-up delays — reducing response times from an industry average of 5 days to real-time execution — while boosting lead conversion rates from 47% to over 70%.

"Trade shows and B2B exhibitions are among the most critical channels for international expansion, yet companies routinely lose valuable opportunities in the days following an event due to delayed execution," said Haeil Yi, Chief Executive Officer of CoBALT. "REALIZER was built to bridge that gap. Our deployment at WABA Korea Expo demonstrates how AI can strengthen human relationships and turn initial handshakes into measurable business outcomes. This partnership marks an exciting first step in CoBALT's expansion across North America."

"WABA Korea Expo was created to build lasting bridges between businesses across Korea and the United States," said Myung Kyu Oh, President of KACCWA. "The biggest challenge for exhibitors has always been preserving relationship momentum after the event closes. Partnering with CoBALT ensures our attendees have the AI tools needed to convert meaningful conversations into long-term commercial partnerships."

Operating across major global markets — including the U.S., Singapore, Japan, South Korea, and the UAE — REALIZER has earned international recognition at premier technology forums, including GITEX Supernova and the Slingshot Global Competition.

Following WABA Korea Expo 2026, CoBALT plans to expand REALIZER across North American trade shows, industry conferences, chambers of commerce, and enterprise sales organizations.

About CoBALT

CoBALT is a global AI SaaS company developing intelligent solutions that maximize the value of in-person business interactions. Its flagship platform, REALIZER, combines AI-driven contact capture, relationship intelligence, and automated follow-up to reduce administrative burden and accelerate pipeline growth for global B2B teams. Operating from Singapore and Seoul, CoBALT serves enterprise and mid-market clients across North America, Asia, and the Middle East. For more information, visit www.realizer.ai.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

CoBALT Expands to U.S. Market with AI Business Engagement Platform REALIZER